Biointerface membranes incorporating bioactive agents
AssigneeDexCom, Inc.
InventorsMark Shults, James H. Brauker, Victoria Carr-Brendel, Mark Tapsak, Dubravka Markovic
Life of this patent
Estimating the term…
Abstract
A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.
Claims25
An implantable glucose sensor having a biointerface membrane comprising:
- a first domain comprising a nonresorbable solid portion comprising a plurality of interconnected cavities having a pore size greater than about 30 μm, as determined by a bubble point test measurement, wherein the solid portion is adapted to support a tissue ingrowth in vivo;
- a second domain located adjacent to the first domain, wherein the second domain is impermeable to cells or cell processes and is configured to allow a passage of glucose therethrough;
- and
- a bioactive agent incorporated into the biointerface membrane, wherein the bioactive agent is capable of modifying a tissue response in such a way that sleep period effects on the implantable glucose sensor are reduced, wherein the bioactive agent is configured to be released from the first domain and/or the second domain.
An implantable glucose sensor having a biointerface membrane comprising:
- a first domain comprising a nonresorbable solid portion comprising a plurality of interconnected cavities having a pore size greater than about 30 μm, as determined by a bubble point test measurement, wherein the solid portion is adapted to support a tissue ingrowth in vivo;
- a second domain located adjacent to the first domain, wherein the second domain is impermeable to cells or cell processes and is configured to allow a passage of glucose therethrough;
- and
- a pro-inflammatory agent incorporated into the biointerface membrane, wherein the pro-inflammatory agent is capable of modifying a tissue response in such a way that sleep period effects on the implantable glucose sensor are reduced, wherein the pro-inflammatory agent is configured to be released from the first domain and/or the second domain.
Dependencies are inferred from the claim text.